Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: ML-193 is a potent antagonist of GPR55 (IC50 = 221 nM). It displays selectivity for GPR55 over CB1, CB2, and GPR35. ML-193 inhibits GPR55-dependent ERK phosphorylation (IC50 = 65 nM) and blocks translocation of PKC beta II. ML-193 blocks increases in intracellular calcium levels induced by lysophosphatidylinositol (LPI) in dissociated rat periaqueductal gray neurons and modulates pain perception in LPI-treated rats.
ML-193 is supplied as a crystalline solid. A stock solution may be made by dissolving the ML-193 in the solvent of choice. ML-193 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of ML-193 in these solvents is approximately 0.1, 2, and 3 mg/ml, repsectively. ML-193 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ML-193 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. ML-193 has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.
Heynen-Genel, S., Dahl, R., Shi, S., et al. Screening for selective ligands for GPR55 - antagonists. NIH Mol. Libraries (2010).
Kotsikorou, E., Sharir, H., Shore, D. M. et al. Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry 52(52), 9456-9469 (2013).
Deliu, E., Sperow, M., Console-Bram, L., et al. The lysophosphatidylinositol receptor GPR55 modulates pain perception in the periaqueductal gray. Mol. Pharmacol. 88(2), 265-272 (2015).